Last reviewed · How we verify
Ex-vivo expanded effector cells — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Ex-vivo expanded effector cells (Ex-vivo expanded effector cells) — Dartmouth-Hitchcock Medical Center. Immune effector cells are collected from patients, expanded in laboratory culture to increase their numbers, then reinfused to enhance immune response.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ex-vivo expanded effector cells TARGET | Ex-vivo expanded effector cells | Dartmouth-Hitchcock Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ex-vivo expanded effector cells CI watch — RSS
- Ex-vivo expanded effector cells CI watch — Atom
- Ex-vivo expanded effector cells CI watch — JSON
- Ex-vivo expanded effector cells alone — RSS
Cite this brief
Drug Landscape (2026). Ex-vivo expanded effector cells — Competitive Intelligence Brief. https://druglandscape.com/ci/ex-vivo-expanded-effector-cells. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing